Treatment of Tuberculosis — Adjuvant Therapies to Increase the Efficiency of Antibiotics

There is growing evidence that resistance to Mycobacterium tuberculosis infection is governed in large part by the regulation of host cell death. Lipid mediators called eicosanoids are thought to play a central role in this process. The subject invention is a novel method of enhancing the efficacy of antibiotic treatments for Mycobacterium tuberculosis infection by co-administering an inhibitor of 5-lipoxygenase and a COX-2 dependent prostaglandin. Inhibition of 5-lipoxygenase and treatment with prostaglandin E2 results in alteration of the eicosanoid balance. The synergistic effects of altering the eicosanoid balance and treatment with antibiotics is believed to result in more efficient reduction of the bacterial burden and thus, the period of antibiotic administration and antibiotic dosage could potentially be reduced. In vivo data from mouse models can be provided upon request.

Potential Commercial Applications: Competitive Advantages:
An adjuvant therapy for existing antibiotic treatment regiments against tuberculosis.   Increase the efficacy of existing antibiotic treatments for tuberculosis, potentially reducing both the duration and dosage of the antibiotic treatment.

Katrin Mayer (NIAID)
Bruno Bezerril Andrade (NIAID)
F. Alan Sher (NIAID)
Daniel Barber (NIAID)

Intellectual Property:
US Application No. 61/515,229
US Application No. 61/515,237
PCT Application No. PCT/US2012/049280

Licensing Contact:
Kevin Chang , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
Phone: 301-435-5018
Fax: 301-402-0220

OTT Reference No: E-189-2011/0

Updated: 07/05/2013